(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Exceptionally Appraised Summer Travel Objections - 2Share your pick for the riding area that characterizes your surf undertakings!
- 3Incredible Travel Objections for Craftsmanship Darlings to Visit
- 4Ten Awesome Authentic Realities That Will Leave You Interested
- 5Most loved Broiled Chicken: Which Chain Rules?
- What’s the shadowy organisation taking Gaza Palestinians to South Africa?
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
- An Extended time of Self-Reflection: Self-awareness through Journaling
- Make your choice for the music application with the most amicable connection point!
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
- The Specialty of Compromise: Examples from Reality
- Make your choice for the sweet that transports you to its nation of beginning!
- Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
